Abstract
Drug resistance is the most common cause of relapses and represents a major limitation for successful management of advanced cancers. Patients with relapse often experience an aggressive progression of the disease. The use of conventional chemotherapy drug combinations remains of limited success given the common occurrence of a broad cross-resistance toward structurally and functionally unrelated drugs. Initial optimism surrounding modulation of single cellular drug resistance markers identified in preclinical models has resulted in very limited predictive and clinical benefit primarily because of alternative mechanisms that operate in drug resistant cancer cells. Even modulators can become entangled in the same problems that they were intended to solve, namely cell resistance to the modulator itself. The recent shift in the use of targeted agents, particularly those targeting tyrosine kinase receptors and signaling components, has provided exciting clinical results. In particular, recent clinical trials have demonstrated the utility of these targets as surrogate markers to guide the selection of patient populations susceptible to respond to treatment. Yet, these optimisms are tempered in part because resistance to targeted therapies is now documented to occur in experimental models and in the clinic. This review interface mechanisms of drug resistance to targeted therapies versus non-specific chemotherapy, with emphasis on fundamental challenges to be resolved to improve the therapeutic management of refractory cancers.
Keywords: Cancer, drug resistance, targeted therapy
Current Cancer Therapy Reviews
Title: New Targets, New Agents, and the Evolving Phenomena of Drug Resistance in Cancer
Volume: 2 Issue: 1
Author(s): Shi-Ping Luh and Moulay A. Alaoui-Jamali
Affiliation:
Keywords: Cancer, drug resistance, targeted therapy
Abstract: Drug resistance is the most common cause of relapses and represents a major limitation for successful management of advanced cancers. Patients with relapse often experience an aggressive progression of the disease. The use of conventional chemotherapy drug combinations remains of limited success given the common occurrence of a broad cross-resistance toward structurally and functionally unrelated drugs. Initial optimism surrounding modulation of single cellular drug resistance markers identified in preclinical models has resulted in very limited predictive and clinical benefit primarily because of alternative mechanisms that operate in drug resistant cancer cells. Even modulators can become entangled in the same problems that they were intended to solve, namely cell resistance to the modulator itself. The recent shift in the use of targeted agents, particularly those targeting tyrosine kinase receptors and signaling components, has provided exciting clinical results. In particular, recent clinical trials have demonstrated the utility of these targets as surrogate markers to guide the selection of patient populations susceptible to respond to treatment. Yet, these optimisms are tempered in part because resistance to targeted therapies is now documented to occur in experimental models and in the clinic. This review interface mechanisms of drug resistance to targeted therapies versus non-specific chemotherapy, with emphasis on fundamental challenges to be resolved to improve the therapeutic management of refractory cancers.
Export Options
About this article
Cite this article as:
Luh Shi-Ping and Alaoui-Jamali A. Moulay, New Targets, New Agents, and the Evolving Phenomena of Drug Resistance in Cancer, Current Cancer Therapy Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339406775471821
DOI https://dx.doi.org/10.2174/157339406775471821 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Treatment of Cancer in the Elderly)
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Bacteriochlorins and Their Potential Utility in Photodynamic Therapy (PDT)
Current Organic Chemistry Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effect of Alcohol on Gastrointestinal Motility
Reviews on Recent Clinical Trials Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry An Illustrative Review of Solid Pancreatic Masses: Differential Diagnostic Features of CT and MRI Findings
Current Medical Imaging Probiotics and Different Efficacy, How it can be Managed?
Current Drug Therapy Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective
Current Medicinal Chemistry Effects of Hyperlipidemia and Cardiovascular Diseases on Proliferation, Differentiation and Homing of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Natural Product Gossypol and its Derivatives in Precision Cancer Medicine
Current Medicinal Chemistry Choline Kinase Alpha Depletion Selectively Kills Tumoral Cells
Current Cancer Drug Targets A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Radiolabeling Methods and Nuclear Imaging Techniques in the Design of New Polymeric Carriers for Cancer Therapy
Current Applied Polymer Science Serotonin and Cancer: What Is the Link?
Current Molecular Medicine